There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Castle Biosciences (CSTL – Research Report), Axonics Modulation Technologies (AXNX – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments.
Castle Biosciences (CSTL)
In a report issued on October 5, Catherine Ramsey Schulte from Robert W. Baird reiterated a Buy rating on Castle Biosciences, with a price target of $30.00. The company’s shares closed last Friday at $14.45.
According to TipRanks.com, Schulte is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $33.40 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Axonics Modulation Technologies (AXNX)
In a report issued on October 5, David Rescott from Robert W. Baird maintained a Buy rating on Axonics Modulation Technologies, with a price target of $70.00. The company’s shares closed last Friday at $58.22.
According to TipRanks.com, Rescott is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axonics Modulation Technologies with a $75.38 average price target.
Apellis Pharmaceuticals (APLS)
In a report issued on October 5, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $70.00. The company’s shares closed last Friday at $41.03.
According to TipRanks.com, Kusy has 0 stars on 0-5 stars ranking scale with an average return of
Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $68.17, which is a 68.0% upside from current levels. In a report issued on October 6, J.P. Morgan also upgraded the stock to Buy with a $81.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CSTL:
- Castle Biosciences management to meet virtually with Stephens
- Castle Biosciences announces publication of TissueCypher test data
- Castle Biosciences gets ‘NY Laboratory Permit’ for Pittsburgh facility
- Castle Biosciences management to meet with KeyBanc
- Castle Biosciences announces new TissueCypher study data published
